Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Eli Lilly
AI-generated illustration
OrganisationUS

Eli Lilly

US drugmaker behind Kisunla; backed two British biotech rounds in five days in November 2026.

Last refreshed: 14 November 2026 · Appears in 1 active topic

Key Question

Why is Eli Lilly buying minority stakes in British biotech?

Timeline for Eli Lilly

#17 10 Nov

Joined Oyster's Series A as a new investor

UK Startups and Innovation: Oyster brings Eli Lilly into $60m round
#17 5 Nov

Joined T-Therapeutics' Series B

UK Startups and Innovation: T-Therapeutics raises $133m in Series B
View full timeline →

Background

Eli Lilly put money into two British biotech rounds within five days in November 2026, both times as a minority investor behind a specialist lead. It joined T-Therapeutics' $133m Series B on 5 November and Oyster Therapeutics' $60m Series A on 10 November as a new strategic investor.

The Indianapolis drugmaker sells Kisunla, an antibody that clears amyloid, one of the two proteins linked to Alzheimer's disease. Oyster's degrader targets tau, the other, so the stake gives Lilly an early view of the next mechanism without building it in-house.

Buying in at Series A and B gives a drugmaker early sight of clinical data and a seat near later licensing talks, without setting the price.

Common Questions
Which British biotechs has Eli Lilly invested in?
In November 2026 Lilly joined T-Therapeutics' $133m Series B and Oyster Therapeutics' $60m Series A, both as a minority investor.Source: BioPharm International; BioIndustry Association
Why did Eli Lilly invest in Oyster Therapeutics?
Oyster is developing a degrader aimed at tau in Alzheimer's. Lilly already sells Kisunla, which targets amyloid, so the stake gives it an early view of a second mechanism.Source: BioIndustry Association
What does Eli Lilly sell for Alzheimer's?
Kisunla, an antibody that clears amyloid from the brain.Source: Eli Lilly
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.